RXi targets dermal cells with RNA delivery method

By Nick Taylor

- Last updated on GMT

Related tags: Scientific method, Pre-clinical development

RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.

Self delivering rxRNA (sd-rxRNA) has been developed to overcome the difficulties faced in administering RNA. RXi claims its preclinical research has demonstrated spontaneous cellular uptake into dermal cells and silencing of the targeted mRNA.

Pamela Pavco, vice president (VP) of pharmaceutical development at RXi, explained that the company is now trying to find the best candidates for particular applications. The goal is to move these candidates into non-clinical and then into clinical trials.

RXi is researching the use sd-rxRNA for both systemic and local administration.

Related topics: Delivery technologies, Ingredients

Related news

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us

Products

View more

Webinars